UCL 2077 |
| Catalog No.GC13188 |
UCL 2077 est un bloqueur sélectif des canaux après hyperpolarisation lente (sAHP) (IC50 =500 nM dans les neurones hippocampiques en culture), ayant des effets minimes sur les canaux Ca2+, les potentiels d'action, la résistance d'entrée et le milieu après l'hyperpolarisation.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 918311-87-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC50 = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization[1]. UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels[2].
References:
[1]. Shah MM, et al. Enhancement of hippocampal pyramidal cell excitability by the novel selective slow-afterhyperpolarization channel blocker 3-(triphenylmethylaminomethyl)pyridine (UCL2077). Mol Pharmacol. 2006 Nov;70(5):1494-502.
[2]. Soh H, et al. The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels. Mol Pharmacol. 2010 Dec;78(6):1088-95.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *